{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oxacillin", "query": { "intervention": "Oxacillin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 16, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oxacillin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T08:42:47.765Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00077675", "title": "Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infections, Gram-positive Bacterial" ], "interventions": [ { "name": "Telavancin", "type": "DRUG" }, { "name": "vancomycin or antistaphylococcal penicillin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cumberland Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2004-02", "completion_date": "2004-09", "has_results": true, "last_update_posted_date": "2019-01-16", "last_synced_at": "2026-09-06T08:42:47.765Z", "location_count": 1, "location_summary": "National City, California", "locations": [ { "city": "National City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077675" }, { "nct_id": "NCT05977868", "title": "Comparing Oral Versus Parenteral Antimicrobial Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Endovascular Infection", "Bone and Joint Infection", "Skin and Soft Tissue Infection", "Pulmonary Infection", "Gastrointestinal Infection", "Genitourinary Infection" ], "interventions": [ { "name": "Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid", "type": "DRUG" }, { "name": "Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West Virginia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2023-08-04", "completion_date": "2025-02-14", "has_results": true, "last_update_posted_date": "2025-08-26", "last_synced_at": "2026-09-06T08:42:47.765Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05977868" }, { "nct_id": "NCT00061633", "title": "Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infections, Gram-Positive Bacterial", "Abscess", "Burns", "Cellulitis", "Ulcer", "Wound Infections" ], "interventions": [ { "name": "Telavancin", "type": "DRUG" }, { "name": "Vancomycin or antistaphylococcal penicillin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cumberland Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2003-06", "completion_date": "2004-01", "has_results": true, "last_update_posted_date": "2019-01-16", "last_synced_at": "2026-09-06T08:42:47.765Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00061633" }, { "nct_id": "NCT02099240", "title": "Patients Response to Early Switch To Oral:Osteomyelitis Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Osteomyelitis" ], "interventions": [ { "name": "oral antibiotics", "type": "DRUG" }, { "name": "intravenous antibiotics", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Julio Ramirez", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 11, "start_date": "2014-03-06", "completion_date": "2018-11-07", "has_results": false, "last_update_posted_date": "2021-04-06", "last_synced_at": "2026-09-06T08:42:47.765Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02099240" }, { "nct_id": "NCT00711802", "title": "Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Skin Diseases, Infectious" ], "interventions": [ { "name": "Daptomycin", "type": "DRUG" }, { "name": "Standard of Care (SOC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Year to 17 Years" }, "enrollment_count": 396, "start_date": "2008-07-23", "completion_date": "2013-10-11", "has_results": true, "last_update_posted_date": "2018-09-05", "last_synced_at": "2026-09-06T08:42:47.765Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Oakland, California • Orange, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00711802" }, { "nct_id": "NCT00428844", "title": "Study of Daptomycin in Subjects Undergoing Surgery for Osteomyelitis Associated With an Infected Prosthetic Caused by Staphylococci", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Osteomyelitis" ], "interventions": [ { "name": "daptomycin", "type": "DRUG" }, { "name": "vancomycin", "type": "DRUG" }, { "name": "teicoplanin", "type": "DRUG" }, { "name": "nafcillin", "type": "DRUG" }, { "name": "oxacillin", "type": "DRUG" }, { "name": "flucloxacillin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 75, "start_date": "2007-06-26", "completion_date": "2010-06-23", "has_results": true, "last_update_posted_date": "2018-01-31", "last_synced_at": "2026-09-06T08:42:47.765Z", "location_count": 17, "location_summary": "Little Rock, Arkansas • Englewood, Colorado • Washington D.C., District of Columbia + 14 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" }, { "city": "Idaho Falls", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT00428844" }, { "nct_id": "NCT01191840", "title": "Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bacteremia" ], "interventions": [ { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 509, "start_date": "2011-02", "completion_date": "2017-03-04", "has_results": true, "last_update_posted_date": "2018-01-05", "last_synced_at": "2026-09-06T08:42:47.765Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 11 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01191840" }, { "nct_id": "NCT02814916", "title": "Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Methicillin-Resistant Staphylococcus Aureus", "Bacterial Infections", "Staphylococcal Skin Infections" ], "interventions": [ { "name": "Dalbavancin", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" }, { "name": "Oxacillin", "type": "DRUG" }, { "name": "Flucloxacillin", "type": "DRUG" }, { "name": "Cefadroxil", "type": "DRUG" }, { "name": "Clindamycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "0 Years to 17 Years" }, "enrollment_count": 199, "start_date": "2017-03-30", "completion_date": "2024-01-01", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-06T08:42:47.765Z", "location_count": 15, "location_summary": "Mobile, Alabama • Phoenix, Arizona • La Palma, California + 12 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Palma", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02814916" }, { "nct_id": "NCT04775953", "title": "DOTS: Dalbavancin as an Option for Treatment of Staphylococcus Aureus Bacteremia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Staphylococcal Bacteraemia" ], "interventions": [ { "name": "Cefazolin", "type": "DRUG" }, { "name": "Dalbavancin", "type": "DRUG" }, { "name": "Daptomycin", "type": "DRUG" }, { "name": "Nafcillin", "type": "DRUG" }, { "name": "Oxacillin", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 200, "start_date": "2021-04-22", "completion_date": "2023-12-01", "has_results": true, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-09-06T08:42:47.765Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Sacramento, California • Torrance, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04775953" }, { "nct_id": "NCT05156437", "title": "Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Endocarditis" ], "interventions": [ { "name": "Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin", "type": "DRUG" }, { "name": "Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "West Virginia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2022-03-16", "completion_date": "2024-10-31", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-09-06T08:42:47.765Z", "location_count": 1, "location_summary": "Morgantown, West Virginia", "locations": [ { "city": "Morgantown", "state": "West Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05156437" } ] }